1 Burden, Causation, and Particularities of long-COVID in African populations: A

2 rapid systematic review

4 Authors: Peter S. Nyasulu<sup>1,2\*\*</sup>, Jacques L. Tamuzi<sup>1</sup>, Rajiv T. Erasmus<sup>3</sup>

Affiliations

3

5

6

14

18

19

20

21

22

23

24

- <sup>7</sup> Department of Global Health, Faculty of Medicine and Health Sciences,
- 8 Stellenbosch University, Cape Town, South Africa
- <sup>9</sup> School of Public Health, Faculty of Health Sciences, University of the
- 10 Witwatersrand, Parktown, Johannesburg, South Africa.
- <sup>3</sup>Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and
- Health Sciences, Stellenbosch University & NHLS Tygerberg Hospital, Cape Town,
- 13 South Africa
- 15 \*\*Corresponding author: Professor Peter Nyasulu. Division of Epidemiology and
- Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences,
- 17 Stellenbosch University, Cape Town, South Africa. pnyasulu@sun.ac.za

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Abstract Background: The global estimated prevalence of long COVID-19 is 43%, and the most common symptoms found globally are fatigue, confusion, or lack of confusion, and dyspnea, with prevalence rates of 23%, 14%, and 13%, respectively. However, long COVID still lacks an overall review in African populations. The aim of this review was to determine the prevalence of long COVID, its most common symptoms, comorbidities, and pathophysiological mechanisms. **Methods:** A systematic review of long COVID in African populations was conducted. The random effects model was used to calculate the pooled prevalence rates (95% CI). If the results could not be pooled, a narrative synthesis was performed. Results: We included 14 studies from 7 African countries, totaling 6,030 previously SARS-CoV-2 infected participants and 2,954 long COVID patients. Long COVID had a pooled prevalence of 41% [26%-56%]. Fatigue, dyspnea, and confusion or lack of concentration were the most common symptoms, with prevalence rates (95% CI) of 41% [26%-56%], 25% [12%-38%], and 40% [12%-68%], respectively. Long COVID was associated with advanced age, being female, more than three long COVID symptoms in the acute phase, initial fatigue and dyspnea, post-recovery stress, sadness, and sleep disturbances, and loss of appetite at symptoms onset, mild, moderate, and severe, pre-existing obesity, hypertension, diabetes mellitus, and the presence of any chronic illness (P ≤0.05). According to our review, high micro clot and platelet poor plasma (PPP) viscosity explain the pathophysiology of long COVID. Conclusion: Long COVID prevalence in Africa was comparable to the global prevalence. However, the prevalence of the most common symptoms was higher in

Africa. Comorbidities associated with long COVID may lead to additional

complications in African populations due to hypercoagulation and thrombosis.

Key words: Long COVID, prevalence, symptoms, comorbidities, pathophysiology,

African populations

## 1. Background

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Post-Acute Seguelae of severe acute respiratory coronavirus 2 (SARS-CoV-2) (PASC), colloquially referred to as "long coronavirus disease (COVID)", is a poorly understood condition characterized by prolonged COVID-19 symptoms and/or the development of new symptoms following the resolution of acute SARS-CoV-2 infection. While there is still no formal clinical definition of long COVID, findings reported in individuals experiencing long COVID include general symptoms (tiredness or fatigue that interferes with daily life, symptoms that get worse after physical or mental effort (also known as "post-exertional malaise"), fever, respiratory and heart symptoms (difficulty in breathing or shortness of breath, cough, chest pain, fast-beating or heart palpitations, neurological symptoms (difficulty thinking or concentrating, headache, insomnia, dizziness, pins-and-needles feelings, change in smell or taste, depression or anxiety), digestive symptoms (Gastroesophageal reflux disease (GERD), diarrhoea, and stomach pain) and other symptoms (hyperlipidaemia, thromboembolism, kidney disorders, joint or muscle pain, rash and changes in menstrual cycles). 1-4 For example, National Institute for Health and Care Excellence (NICE) defined the "Long COVID" as "signs and symptoms that develop during/after the COVID-19 infection persisting for more than 4 weeks and could not be explained by any other diagnosis". In this categorization, the long COVID consists of two categories, "ongoing symptomatic COVID-19", which indicates the symptoms last for 4-12 weeks; and "post-COVID-19 syndrome", which means symptom persistence beyond 12 weeks.<sup>5,6</sup> Baig et al. suggested using the term "Chronic COVID syndrome (CCS)" as opposed to "Long-COVID" or "Long Haulers". He also presented an organ-based staging of the illness to prioritize immediate care needs.<sup>5,7</sup>

As of 21 December 2022, Africa recorded approximately 9.4 million confirmed COVID-19 cases accounting for just 1.45 % of 649,2 million global COVID-19 confirmed cases<sup>8</sup>, despite containing 12.5% of the global population. <sup>9,10</sup> In Africa, the picture of long COVID is not well described as little research has been conducted in this emerging field. However, few studies have been conducted on the burden of long COVID in Africa, long COVID prevalence has been reported to vary across and within African countries. Dryden et al. reported the highest long COVID prevalence compared to other studies conducted worldwide. <sup>11</sup> However, a single study cannot reflect the prevalence of the African continent. While Peluso et al. concluded that HIV status strongly predicted the presence of long COVID. <sup>12</sup> Other studies found that diabetes, cardiovascular disease, and female sex were all linked to long COVID. <sup>13,14</sup> Given the high prevalence of these comorbidities on the African continent, an overall study focusing on African populations is required. We determined the burden of long COVID, prevalent symptoms, key findings, risk factors, and plausible pathophysiology in African populations in this review.

#### 2. Methods

This section covers study selection strategy, study design, eligibility, inclusive and exclusive criteria, and quality of assessment and synthesis.

## 2.1. Study selection strategy

To ensure the reproducibility and transparency of our findings, studies were selected for systematic reviews (from January 2020 to December 2022) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>15</sup> The studies were chosen based on the following key review research questions: How prevalent is long COVID in African populations? What are the most

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

prevalent long COVID symptoms in African populations? What factors and comorbidities are associated with long COVID in African populations? To respond these questions, we searched PubMed, Medline, Google Scholar, the WHO COVID-19 Research Database, medRxiv, and bioRxiv for potential studies on long COVID-19 in African populations, employing the following MESH terms and key words as the search strategy: "Post-Acute COVID-19 Syndromes" OR "Long Haul COVID-19" OR "Long COVID" OR "Post-Acute Sequelae of SARS-CoV-2 Infection" OR "Post-COVID Conditions" OR "Post-COVID Condition" OR "Long-Haul COVID" AND "Comorbidities" AND "epidemiology" [Subheading] OR "Burden of Disease" AND "African populations" OR "African people" OR "Africans". Only English-language studies were considered. To remove duplicates, studies were imported into the Endnote online tool. The authors took a step-by-step approach, beginning with systematic reviews. The remaining abstracts were screened by one reviewer, and all excluded abstracts were screened by another. One reviewer screened all full-text papers, and a second screened those that were not. When necessary, a third reviewer was brought in. One reviewer (JLT) extracted the data, and another (PSN) double-checked it. The study ID, setting, population, long COVID prevalence, comorbidities, and statistically significant findings were all included in the data. The Newcastle-Ottawa Scale (NOS) risk of bias assessment was used to evaluate the study's quality.16

#### 2.2. Study design eligible inclusion and exclusion criteria

We only included studies that looked at long COVID prevalence, symptoms, associated comorbidities, and other important findings in African populations. This review included people of all ages. We also included African studies on COVID

symptoms that persisted. Furthermore, studies on asymptomatic COVID-19 and

those assessing COVID recovery time were excluded from this review.

### 2.3. Data extraction and synthesis

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

We created a data extraction table to collect information related to the research questions. However, data were extracted for the four most common long COVID symptoms. Data extraction was completed by one reviewer (JLT) and independently checked by a second reviewer (PSN), with discrepancies resolved through discussion. Only evidence directly relevant to the review question was extracted. The data included in the meta-analysis, primarily long COVID prevalence and the four most common symptoms, were extracted into an Excel spreadsheet and the effect sizes (ES) and standard errors were calculated. Long COVID prevalence was calculated for each included study by dividing the total number of SARS-CoV-2 infected patients by the total number of long COVID. The number of COVID-19 patients with symptoms divided by the total number of long COVID patients yielded the prevalence for each long COVID symptom. A meta-analysis was performed for long COVID prevalence and the four most common symptoms. According to the Cochrane handbook<sup>17</sup>, the prevalence rates were pooled using the random effects model because we expected significant heterogeneity (I<sup>2</sup>>50%). Subgroup analyses based on setting and long COVID were performed a priori. For small sample studies, Egger's regression and Begg's tests were used to assess publication bias. The P-value for statistical significance was set at 0.05 for all analyses. Stata (V.16, Stata Corp, College Station, Texas, USA) was used for the meta-analysis. Comorbidities and key findings were summarized in a narrative format.

#### 3. Results

The databases yielded 453 articles, 39 duplicates were removed, and 414 titles and abstracts were screened for eligibility. 387 records were excluded because they were unsuitable for the review. Full texts were obtained for the 27 studies, but 13 were excluded because two were protocols, nine were reports, and two were letters to the editors. Then, 14 studies were included in our analysis, with 9 included in the meta-analysis and 5 included in the narrative synthesis. The review flow chart is shown in Figure 1.






Figure 1: Flow chart of studies reviewing long COVID in African populations

## 3.1. Study and participant characteristics

Fourteen studies were included in this review. Among them, five were case control studies conducted in South Africa and Morocco<sup>18-22</sup>, three retrospective cohort studies undertaken in Nigeria and South Africa<sup>23-25</sup>, two prospective cohort studies (South Africa and Zambia)<sup>11,26</sup>, two retrospective cross-sectional studies done in South Africa and Egypt<sup>27,28</sup> and two cross-Sectional studies undertaken Ghana and Egypt<sup>29,30</sup>. This review included a total of 6, 030 previously SARS-CoV-2 infected participants and 2,954 long COVID patients. Seven studies reported that long COVID was prevalent among females. <sup>11,18,20,25-29</sup> In contrast, three studies high prevalence rates among males. <sup>23,24,30</sup> Long COVID range of age was 1 to 85 years. <sup>11,18,19,22-24,27,28,30</sup> Methodological quality of the included studies was reported in Supplementary file 1.

#### 3.2. Meta-analysis

The pooled results of long COVID prevalence (95% CI) in African populations revealed a 41% [26%-56%] overall prevalence (**Figure 2**). This prevalence, however, varied significantly across studies conducted in different African countries. Egypt had the highest prevalence, at 59% [55%-64%] (**Figure 2**). Nigeria had a prevalence rate of 49% [31%-66%]. (Figure 2). South Africa, Morocco, and Zambia had prevalence rates of 47% [7%-86%], 47% [38%-56%], and 15% [10%-20%], respectively (**Figure 2**). Ghana had the lowest prevalence of 2% [2%-3%] (**Figure 2**). The degree of heterogeneity between studies was high, with I<sup>2</sup> = 99.5%.

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

The prevalence of the most common long COVID symptoms in African populations was assessed in Figure 3. According to the pooled prevalence, fatigue, dyspnea, and confusion or lack of concentration were the most common and prevalent long COVID symptoms among African populations. Fatigue, dyspnea, and confusion or lack of concentration were all prevalent (95% CI) at 41% [26%-56%], 25% [12%-38%], and 40% [12%-68%], respectively (Figure 3). A study of 845 long COVID participants found that fatigue, brain fog, loss of concentration and forgetfulness, dyspnea, and joint and muscle pains were the most common symptoms in African populations (**Table 1**). However, due to missing data, we were unable to include this in the meta-analysis. Other common symptoms were arthralgia, myalgia, depression, chest pain, headache, anxiety, and cough (Figure 3). Even though the test of heterogeneity between studies was high ( $1^2 = 97.60\%$ ), the test of group difference was not statistically significant (P = 0.43). Using Egger's regression and Begg's tests, we assessed the publication bias of nine studies that included long COVID prevalence in African populations. With z = 1.49 (P = 0.1538) and z = -0.52 (P = 1.3978), the publication bias was less likely.




Figure 2: Forest plot of long COVID prevalence in African countries

255




Figure 3: Forest plot of predominant symptoms of long COVID in African populations

#### 3.3. Narrative synthesis

The narrative synthesis reported all statistically significant key findings (P 0.05) and important findings related comorbidities associated with long COVID and pathophysiology.

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Long-COVID was statistically associated with advanced age and female sex in African populations (P ≤0.05). 11,28 In terms of clinical symptoms, long COVID was statistically associated with more than three long COVID symptoms in the acute phase, including initial fatigue and dyspnea, post-recovery stress, sadness and sleep disturbances, and loss of appetite at symptoms onset (P ≤0.05). 11,26,27,28 Our review also found that long COVID was statistically associated with mild, moderate, and severe COVID-19 (P ≤0.05).11,23,24,28 Long COVID was also associated with supplemental oxygen during intensive care unit (ICU) admission and pulmonary involvement in chest CT scan (P ≤0.05). 11,20,29 Obesity, hypertension, diabetes mellitus, and the presence of any chronic illness were all statistically significant predictors of long COVID. 11,29,30 The most common comorbidities found in long COVID in African populations were hypertension, obesity, hyperlipidaemia, diabetes mellitus, human immunodeficiency virus (HIV), ischemic heart disease, chronic obstructive pulmonary disease (COPD)/asthma, malignancies, previous tuberculosis (TB), renal disease, thrombosis (previous blood clots), and psychiatric diseases, as shown in **Table 1** and **Figure 4**. In terms of pathophysiology, African studies found that long COVID patients had higher microclot and platelet poor plasma (PPP) viscosity when compared to control groups. 18,21,22,25 Furthermore, high levels of six inflammatory molecules were detected, including serum Amyloid A (SAA), -2 antiplasmin (-2AP), platelet factor 4 (PF4), Von Willebrand Factor (VWF), endothelial-leukocyte adhesion molecule 1 (E-selectin), and platelet endothelial cell adhesion molecule-1 (PECAM-1).<sup>22</sup>



Figure 1: Potential long COVID risk factors in Africa

#### 4. Discussion

We conducted a systematic review to determine the burden of long COVID, prevalent symptoms, key findings, risk factors, and plausible pathophysiology in African populations. This review included fourteen studies on long COVID conducted in African populations. This study included 6,030 previously SARS-CoV-2 infected participants and 2,954 long COVID patients. Females outnumbered males among long COVID patients. The ages ranged from one to 85 years. The pooled prevalence (95% CI) of long COVID in the African population was 41% [26%-56%]. In comparison to a review of fifty included studies, 41 of which were meta-analysed, the global estimated pooled prevalence of long COVID-19 was 43% [39%-46%]. <sup>13</sup> Long COVID prevalence was higher in Africa than in North America [31% (21%-43%)], but

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

lower in Europe [44% (32%-56%)] and Asia [51% (37%-65%)]. 13 The prevalence (95%CI) of the most common symptoms were 41% [26%-56%] fatigue, 40% [12%-68%] confusion or lack of concentration, and 25% [12%-38%] dyspnoea. Our result was also on same line with a global review showing that the fatigue was the most common symptom reported with a prevalence of 23% [17%-30%]<sup>13,31</sup>, followed by confusion or lack of concentration 14% [10%-19%]<sup>13</sup> and dyspnoea 13% [11%-15%]<sup>13</sup>. Even though the African long COVID prevalence was slightly lower than the global prevalence, the Africans had higher rates of fatigue, confusion or lack of concentration, and dyspnea. Further research may be required to clarify these findings. Our findings also revealed that Long-COVID was statistically associated with advanced age and being female in African populations. 11,28 Our findings were consistent with the findings of Chen et al., who found that female sex was a risk factor for long COVID. Long COVID was statistically associated with more than three long COVID symptoms in the acute phase, including initial fatigue and dyspnea, post-recovery stress, sadness, and sleep disturbances, and loss of appetite at the onset of symptoms. 11,26-28 Our findings support the results from previous systematic review and meta-analysis on long COVID symptoms. 13,31,32 Our study also found that long COVID was statistically associated with mild, moderate, and severe COVID-19. 11,23,24,28 This could be explained by a significant increase in the rates of thrombotic events following even a mild COVID-19 infection. 22,33 Long COVID was also statistically associated with supplemental oxygen during ICU admission and pulmonary involvement in chest CT scan. 11,20,29 A study that looked at the long-term outcomes of patients who needed ICU admission for severe COVID-19 found that the long-term effects of severe COVID-19 lasted

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

more than six months.<sup>34</sup> Similarly, a 12-month study found that a chest CT scan in acute COVID-19 correlates with pulmonary function and respiratory symptoms after SARS-CoV-2 infection.<sup>35</sup> Obesity, hypertension, diabetes mellitus, and the presence of any chronic illness were all statistically significant predictors of long COVID. 11,29,30 Preexisting conditions such as obesity and comorbidities were also found to be positively associated with post COVID-19 condition in multiple studies. 36,37 In point of view pathophysiology, African studies demonstrated high microclot and Platelet poor plasma (PPP) viscosity were statistically higher in long COVID patients compared to the control groups. 18,21,22,25 In addition, high levels of six inflammatory molecules SAA, α-2AP, PF4, VWF, E-selectin and PECAM-1, are known to be key drivers of endothelial and clotting pathology.<sup>22</sup> In fact, long COVID was associated with additional distinctive innate and adaptive immune traits, consisting of a weaker initial inflammatory response.<sup>38</sup> The viral tropism defined by the entry into cells through a widely expressed Angiotensin-Converting Enzyme 2 (ACE2) receptor makes it highly possible that many organs have the potential to undergo not only acute but also chronic damage, adding to the very diverse clinical picture of long COVID. 39,40 Long COVID may generate further complications based on hypercoagulation and thrombosis associated to advanced age and pre-existing comorbidities. As an example, in African populations, a study reported that two people living with HIV (PLWH) developed cardiovascular complications (myocardial infarction and arrhythmia) during the three months of follow-up.41 HIV status was strongly associated with long COVID, raising concerns that this condition might be common among PWH recovering from COVID-19. 12 Certainly, two main hypotheses should be considered. Firstly, it is well known how COVID-19 may cause and worsen cardiovascular events, especially in patients who are at increased risk such as

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

PLWH who also is in increased risk of hypertension, diabetes mellitus, dyslipidaemia, previous thrombosis and obesity. 42,43 Secondly, in patients with known pre-existing cardiovascular risk factors, SAA, α-2AP, PF4, VWF, E-selectin and PECAM-1 induced by the presence of SARS-CoV-2 may have worsened and accelerated the cardiac damage and caused stress cardiomyopathy. 22,41,43,44 Turner et al. explained long COVID as the interaction between endothelial dysfunction, chronic inflammation, and platelet activation generating the formation of micro clot, inducing the raised of the above mentioned six inflammatory molecules and hypercoagulation and thrombosis.<sup>22</sup> This is significant because diabetes type 2 is a risk factor for long COVID in African populations and is associated with hypercoagulation states. 18 Comorbidities associated with an increased risk of long COVID, and hypercoagulability include cardiovascular disease, renal failure, venous thrombosis, cancer, and COPD.<sup>45</sup> Given that Africa has the lowest COVID-19 vaccination rate among continents, this could be another risk factor for long COVID in Africa. A systematic review of six studies (n=17,256,654 individuals) investigating the impact of vaccines before acute SARS-CoV-2 infection found a low level of evidence suggesting that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID infection. 46 As with most common chronic conditions, the causation is not yet well understood. However, long COVID causation should be viewed as a multifactorial interaction between the individual co-morbidities, past medical history, SARS-CoV-2 variants, genetic factors, and ethnicity. Figure 4 in our study has clearly highlighted the multifactorial factors of long COVID in African populations. The reason that some individuals are more prone to develop long COVID possibly lies in their genetic profile primarily related to the immune system, such as human leukocyte antigen (HLA).<sup>5</sup> Long COVID may be the result of tissue/organ damage, or inflammatory and immune pathways dysfunction (including chronic inflammation, hypercoagulation, thrombosis, hyperactive immune cells, and autoimmunity because of molecular mimicry).  $^{11,18,21,22,25}$  This results to difference long COVID prevalence rates and symptoms among populations.

To the best of our knowledge, this is the first systematic review and meta-analysis of long COVID and its most common symptoms. This review will be useful in future research on long COVID and comorbidities in African populations, particularly comorbidities associated with thrombosis risk in African populations. The review's main weaknesses were the small number of included studies, poor study design of included studies, missing data, and high heterogeneity between studies. However, publication bias was less likely because the Egger's regression and Begg's tests were not statistically significant with z = 1.49 (P = 0.1538) and z = -0.52 (P = 1.3978), respectively, and the test of group difference for long COVID symptoms was not statistically significant (P = 0.43).

#### 5. Conclusion

This review looked at the various characteristics of long COVID in Africa. Despite having the lowest number of COVID-19 cases, the prevalence of long COVID cases in Africa was closer to the global prevalence. Even though fatigue, dyspnea, and confusion or lack of concentration were the most common symptoms globally and in Africa, their prevalence rates were higher in Africa. Long COVID was associated with advanced age, female sex, three long COVID symptoms in the acute phase, initial fatigue and dyspnea, post-recovery stress, sadness, and sleep disturbances, and loss of appetite at symptoms onset, mild, moderate, and severe, pre-existing obesity, hypertension, diabetes mellitus, and the presence of any chronic illness in African

populations. According to our review, the pathophysiology of long COVID is explained by high microclot and PPP viscosity. This may raise the risk of additional cardiovascular complications in African populations. Future research should focus on long COVID, and comorbidities associated with hypercoagulation and thrombosis in African populations.

#### 6. Abbreviations

-2AP: -2 antiplasmin; ACE2: Angiotensin-Converting Enzyme 2; AIDS: acquired immune deficiency syndrome; ARDS: acute respiratory distress syndrome; BMI: body mass index; CDC: Centers for Disease Control and Prevention; CCS: Chronic COVID syndrome; CFS: chronic fatigue syndrome; COPD: Chronic obstructive pulmonary disease; COVID-19: Coronavirus disease 2019; E-selectin: endothelial-leukocyte adhesion molecule 1; GORD: Gastroesophageal reflux disease; HIV: human immunodeficiency virus; HLA: human leukocyte antigen; ICU: intensive care unit; MIS-A: multi-system inflammatory syndrome in adults; MIS: multisystem inflammatory syndrome; NICE: National Institute for Health and Care Excellence; PASC: Post-Acute Sequelae of SARS-CoV-2; PECAM-1: platelet endothelial cell adhesion molecule-1; PLWH: persons living with HIV; PF4: platelet factor 4; PPP: platelet poor plasma; RNA: ribonucleic acid; RT-PCR: Reverse transcription polymerase chain reaction; SAA: serum Amyloid A; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; TB: tuberculosis; UN: United Nations; VWF: Von Willebrand Factor; WHO: World Health Organization

#### 6. Footnotes

**Author Contributions:** PSN conceived the review. PSN and JLT searched potential peer review manuscripts. PSN and JLT conducted the data extraction. JLT

429 undertook the data analysis. PSN and JLT drafted the manuscript. PSN, JLT and 430 RTE edited the manuscript. This version was reviewed and approved by all the 431 authors. 432 **Informed Consent Statement:** Not applicable 433 Availability of data and materials: All Data and material are available in this 434 manuscript. **Competing interests:** The authors declare that they have no financial or personal 435 436 relationships that may have inappropriately influenced them in writing this article. 437 Funding Source: None 438 Ethical Approval statement: Not applicable 439 7. References 440 441 1. Aly MAEG, Saber HG. Long COVID and chronic fatigue syndrome: A survey 442 443 of elderly female survivors in Egypt. International journal of clinical practice 444 2021;75(12): e14886. 445 2. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. 446 Characterizing long COVID in an international cohort: 7 months of symptoms 447 and their impact. EClinicalMedicine 2021; 38:101019. 448 Sudre Carole H, Murray Benjamin, Varsavsky Thomas, Graham Mark S, Penfold Rose S, Bowyer Ruth C, et al. Attributes and predictors of long 449 450 COVID. 2021;27(4):626-31. 4. CDC. Long COVID or Post-COVID Conditions. In: 451

https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.

452

453

2022.

- 5. Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar
- S, et al. Long COVID, a comprehensive systematic scoping review. Infection
- 456 2021;49(6):1163-86.
- 6. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of
- 458 post-acute covid-19 in primary care. BMJ (Clinical research ed.)
- 459 2020;370:m3026.
- 7. Baig AM. Deleterious Outcomes in Long-Hauler COVID-19: The Effects of
- SARS-CoV-2 on the CNS in Chronic COVID Syndrome. ACS chemical
- neuroscience 2020;11(24):4017-20.
- 8. WHO. COVID-19 Weekly Epidemiological Update, Edition 123 published 21
- December 2022. <a href="https://www.who.int/publications/m/item/covid-19-weekly-">https://www.who.int/publications/m/item/covid-19-weekly-</a>
- 465 <u>epidemiological-update---21-december-2022</u>
- 9. United Nations Population Division. World Population Prospects. In:
- https://population.un.org/wpp/. 2019.
- 10. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et
- al. What Could Explain the Lower COVID-19 Burden in Africa despite
- 470 Considerable Circulation of the SARS-CoV-2 Virus? International journal of
- environmental research and public health 2021;18(16).
- 11. Dryden M, Mudara C, Vika C, Blumberg L, Mayet N, Cohen C, et al. post-
- 473 COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South
- Africa: a prospective cohort study. The Lancet. Global health 2022;10(9):
- 475 e1247-56.
- 12. Peluso MJ, Spinelli MA, Deveau TM, Forman CA, Munter SE, Mathur S, et al.
- Post acute sequelae and adaptive immune responses in people with HIV

478 recovering from SARS-COV-2 infection. AIDS (London, England) 479 2022;36(12):F7-F16. 480 13. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. 481 Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022 482 483 ;226(9):1593-1607. 14. Rinaldi R, Basile M, Salzillo C, Grieco DL, Caffè A, Masciocchi C, Lilli L, 484 485 Damiani A, La Vecchia G, Iannaccone G, Bonanni A, De Pascale G, Murri R, 486 Fantoni M, Liuzzo G, Sanna T, Massetti M, Gasbarrini A, Valentini V, Antonelli M, Crea F, Montone RA, On Behalf Of The Gemelli Against Covid Group. 487 488 Myocardial Injury Portends a Higher Risk of Mortality and Long-Term 489 Cardiovascular Sequelae after Hospital Discharge in COVID-19 Survivors. J 490 Clin Med. 2022;11(19):5964. 491 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, 492 Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw 493 JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, 494 McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, 495 Moher D. The PRISMA 2020 statement: an updated guideline for reporting 496 systematic reviews. Syst Rev. 2021;10(1):89. 497 16. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers to 498 authors' assessments. BMC Med Res Methodol. 2014 Apr 1; 14:45. doi: 10.1186/1471-2288-14-45. PMID: 24690082; PMCID: PMC4021422. 499 17. Higgins JPT, Green S. eds. Cochrane Handbook for Systematic Reviews of 500 501 Interventions 4.2.6 [updated September 2006]. In: Chichester, UK: John Wiley & Sons, Ltd, 2006:6. The Cochrane Library 502

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

18. Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, Kell DB. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. 19. Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, Pretorius E. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21(1):190. 20. El Otmani H, Nabili S, Berrada M, Bellakhdar S, El Moutawakil B, Abdoh Rafai M. Prevalence, characteristics, and risk factors in a Moroccan cohort of Long-Covid-19. Neurol Sci. 2022;43(9):5175-5180. 21. Walker M, Federico EM, Kell DB, Dupont C, Proal A, Pretorius E. Detection and Characterization of Fibrin/Amyloid Microclots in Patients with Post-Acute Sequelae of Covid-19. Circulation. 2022 Nov 8;146(Suppl 1): A15637-. 22. Turner S, Naidoo C, Usher T, Kruger A, Venter C, Laubscher GJ, Khan MA, Kell DB, Pretorius E. Increased levels of inflammatory molecules in blood of Long COVID patients point to thrombotic endotheliitis. medRxiv. 2022 Jan 1. https://www.medrxiv.org/content/10.1101/2022.10.13.22281055v1 23. Ogoina D, James HI, Ogoinja SZ. Post-Discharge Symptoms among Hospitalized COVID-19 Patients in Nigeria: A Single-Center Study. Am J Trop Med Hyg. 2021;105(3):731-736. 24. Osikomaiya B, Erinoso O, Wright KO, Odusola AO, Thomas B, Adeyemi O, Bowale A, Adejumo O, Falana A, Abdus-Salam I, Ogboye O, Osibogun A,

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

2021;15(1):1-8.

Abayomi A. 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis. 2021;21(1):304. 25. Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, Rajaratnam K, Watson BW, Kell DB. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21(1):148. 26. Zulu JE, Banda D, Hines JZ, Luchembe M, Sivile S, Siwingwa M, Kampamba D, Zyambo KD, Chirwa R, Chirwa L, Malambo W, Barradas D, Sinyange N, Agolory S, Mulenga LB, Fwoloshi S. Two-month follow-up of persons with SARS-CoV-2 infection-Zambia, September 2020: a cohort study. Pan Afr Med J. 2022; 41:26. 27. Aly MAEG, Saber HG. Long COVID and chronic fatigue syndrome: A survey of elderly female survivors in Egypt. Int J Clin Pract. 2021 Dec;75(12): e14886. 28. Mendelsohn AS, Nath N, De Sá A, Von Pressentin KB. Two months follow-up of patients with non-critical COVID-19 in Cape Town, South Africa. S Afr Fam Pract (2004). 2022 Feb 10;64(1): e1-e6. 29. Galal I, Hussein AA, Amin MT, Saad MM, Zayan HE, Abdelsayed MZ, Moustafa MM, Ezzat AR, Helmy RE, Abd Elaal HK, Al Massry NA. Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score. The Egyptian Journal of Bronchology.

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

30. Crankson S, Pokhrel S, Anokye NK. Determinants of COVID-19-Related Length of Hospital Stays and Long COVID in Ghana: A Cross-Sectional Analysis. Int J Environ Res Public Health. 2022;19(1):527. 31. Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, Blyuss O, Bobkova P, Bonsel G, Borzakova S, Buonsenso D, Butnaru D, Carter A, Chu H, De Rose C, Diab MM, Ekbom E, El Tantawi M, Fomin V, Frithiof R, Gamirova A, Glybochko PV, Haagsma JA, Haghjooy Javanmard S, Hamilton EB, Harris G, Heijenbrok-Kal MH, Helbok R, Hellemons ME, Hillus D, Huijts SM, Hultström M, Jassat W, Kurth F, Larsson IM, Lipcsey M, Liu C, Loflin CD, Malinovschi A, Mao W, Mazankova L, McCulloch D, Menges D, Mohammadifard N, Munblit D, Nekliudov NA, Ogbuoji O, Osmanov IM, Peñalvo JL, Petersen MS, Puhan MA, Rahman M, Rass V, Reinig N, Ribbers GM, Ricchiuto A, Rubertsson S, Samitova E, Sarrafzadegan N, Shikhaleva A, Simpson KE, Sinatti D, Soriano JB, Spiridonova E, Steinbeis F, Svistunov AA, Valentini P, van de Water BJ, van den Berg-Emons R, Wallin E, Witzenrath M, Wu Y, Xu H, Zoller T, Adolph C, Albright J, Amlag JO, Aravkin AY, Bang-Jensen BL, Bisignano C, Castellano R, Castro E, Chakrabarti S, Collins JK, Dai X, Daoud F, Dapper C, Deen A, Duncan BB, Erickson M, Ewald SB, Ferrari AJ, Flaxman AD, Fullman N, Gamkrelidze A, Giles JR, Guo G, Hay SI, He J, Helak M, Hulland EN, Kereselidze M, Krohn KJ, Lazzar-Atwood A, Lindstrom A, Lozano R, Malta DC, Månsson J, Mantilla Herrera AM, Mokdad AH, Monasta L, Nomura S, Pasovic M, Pigott DM, Reiner RC Jr, Reinke G, Ribeiro ALP, Santomauro DF, Sholokhov A, Spurlock EE, Walcott R, Walker A, Wiysonge CS, Zheng P, Bettger JP, Murray CJL, Vos T. Estimated Global Proportions of Individuals

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-1615. 32. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, Haroon S, Price G, Davies EH, Nirantharakumar K, Sapey E, Calvert MJ; TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428-442. 33. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461-1467. 34. Neville TH, Hays RD, Tseng CH, Gonzalez CA, Chen L, Hong A, Yamamoto M, Santoso L, Kung A, Schwab K, Chang SY, Qadir N, Wang T, Wenger NS. Survival After Severe COVID-19: Long-Term Outcomes of Patients Admitted to an Intensive Care Unit. J Intensive Care Med. 2022;37(8):1019-1028. 35. Steinbeis F, Thibeault C, Doellinger F, Ring RM, Mittermaier M, Ruwwe-Glösenkamp C, Alius F, Knape P, Meyer HJ, Lippert LJ, Helbig ET, Grund D, Temmesfeld-Wollbrück B, Suttorp N, Sander LE, Kurth F, Penzkofer T, Witzenrath M, Zoller T. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respir Med. 2022; 191:106709. 36. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311-321. 37. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590.

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

38. García-Abellán J, Padilla S, Fernández-González M, García JA, Agulló V, Andreo M, Ruiz S, Galiana A, Gutiérrez F, Masiá M. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. J Clin Immunol. 2021;41(7):1490-1501. 39. Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kastritis E, et al. Organ-specific manifestations of COVID-19 infection. Clinical and experimental medicine 2020;20(4):493-506. 40. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet regional health. Europe 2021; 6:100122. 41. Mazzitelli M, Trunfio M, Sasset L, Leoni D, Castelli E, Lo Menzo S, et al. Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA. Viruses 2022;14(3). 42. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature reviews. Cardiology 2020;17(9):543-58. 43. Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, et al. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic. JAMA network open 2020;3(7): e2014780. 44. Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, et al. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection. JAMA cardiology 2021;6(1):116-8.

45. Rahaghi FN, Pistenmaa CL. Hypercoagulation in COPD: the clot thickens.
ERJ Open Res. 2021;7(4):00534-2021.
46. Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al.
Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine 2022; 53:101624.

## Table 1 summarises the evidence-based studies of long COVID-19 in Africa

Study ID/Settings	Study population	Study designs	Long COVID	Predominant	Comorbidities	Key findings
Dryden et al., 2022/South Africa	1,873 enrolled hospitalized COVID-19 participants were followed up three months after hospital discharge. 960 (53·1%) were women and 913 (48·8%) were men, the median age was 52 years (41–62)	A prospective, observational cohort study	prevalence 1,249/1873(66.7%)	symptoms Fatigue (50.3%), shortness of breath (23.4%), confusion or lack of concentration (17.5%), headaches (13.8%), and problems seeing/blurred vision (10.1%).	The most common self-reported comorbidities were hypertension (n=669; 35.7%), obesity (n=474; 25.3%), and diabetes mellitus (n=418; 22.3%). HIV was reported by 95 (5.1%) participants.	age ≥65 years (aOR) 1.62; 95%Cl 1.00- 2.61]; female sex (aOR 2.00; 95% Cl 1.51-2.65); requiring supplemental oxygen during admission (aOR 1.44; 95% Cl 1.06- 1.97); ICU admission (aOR 1.87; 95% Cl 1.36-2.57); pre- existing obesity (aOR 1.44; 95% Cl 1.09- 1.91); and the presence of ≥4 acute symptoms (aOR 1.94; 95% Cl 1.19- 3.15)
Mendelsohn et al., 2022/South Africa	174 long COVID among 653 COVID-19 infected patients. The mean age of participants was 50.3 (13.6) years; 62% were female.	Retrospective cross- sectional study	172/653 (35%)	Fatigue 60 (34.5%) Dyspnoea 35 (20.1%) Loss of taste 34 (19.5%) Loss of smell 32 (18.4%) Headache 27 (15.5%) Body aches 26 (14.9%) Chest pain 19 (10.9%) Gastrointestinal complaints 21 (12.1%) Palpitations 18 (10.3%) Rash 11 (6.3%)	Diabetes 35 (22.0%); Hypertension 77 (48.4%) ischemic heart disease 7 (4.4%) COPD/asthma 10 (6.3%) Prior TB 1 (0.6%) HIV 1 0.6 Other 7 (4.4%)	Sex, age, baseline severity of disease, or number of initial COVID-19 symptoms were predictive of self-reported dyspnoea, fatigue, ≥ 3 long COVID symptoms, or self-reported non-recovery.
Aly et al., 2021/Egypt	A total of 115 females among them 66 had long COVID. The mean age was 73.18 ± 6.42.	A retrospective cross- sectional study	66/115 (57%)	Dyspnoea 20 (17.4) Cough 10 (8.7) Chest pain 9 (7.8) Palpitations 13		The presence of post-recovery symptoms was significantly related

				(11.3) Insomnia 28 (24.3) Headache 14 (12.2) Loss of smell and taste 14 (12.2) Stress 65 (56.5) Sadness 55 (47.8) Fatigue 66 (57.4) Cognitive dysfunction 29 (25.2) Recurrent falls 29 (25.2) Incontinence 21 (18.3)		to stress (P = .005), sadness (P = .007) and sleep disturbances (P < .001)
Crankson et al., 2022/Ghana	2334 patients, among them 50 had long COVID. 60.1% were men and 39.9% were women. The majority were aged from 30 to 59 years (57.5%)	A Cross-Sectional Analysis	50/2334 (2%)	N/A	N/A	COVID-19 patients with hypertension and diabetes mellitus spent almost 2 days longer in hospital (p = 0.00, 95% CI = 1.42–2.33) and had 4 times the odds of long COVID (95% CI = 1.61–10.85, p = 0.003) compared to those with no comorbidities.
Ogoina et al., 2021/Nigeria	51 previously hospitalized COVID-19 patients (median age, 46 years; male, 66.7%) were studied.	Retrospective review	9/51 (17.65%)	Cough: 9 Fatigue: 8 Short of breath: 5 Chest pain: 4 Palpitations: 2 Anxiety: 3 Anorexia: 3	History of diabetes, n (%): 4 History of hypertension, n (%): 8	Mild COVID-19 (P = 0.029)
Osikomaiya et al., 2021/Nigeria	274 patients were enrolled in the study. A majority were within the age group > 35 to ≤49 years (38.3%), and male (66.1%).	A retrospective study design	112/274 (40.9%)	Easy fatigability 35 (12.8) Myalgia 24 (8.8) Cough 25 (9.2) Dyspnea 26 (9.5) Chest pain 27 (9.8) Loss of appetite 24 (8.8) Palpitations 20 (7.4) Headache 35 (12.8)	comorbidities (n = 52), the most common comorbidities were hypertension (72.9%) and diabetes (15.3%)	Moderate COVID-19 (aOR): 2.03 (1.19, 3.47)

				Insomnia 27 (9.8)		
Pretorius et al., 2021/ South Africa	Blood was collected from healthy volunteers (N=13; 6 males, 7 females; mean age: 52.4±4.8) to serve as controls.	Case control study	N/A	N/A	Type 2 diabetes mellitus	A significant difference was noted between Platelet poor plasma (PPP) viscosity of controls and acute COVID-19 (p=0.001) and acute COVID-19 and Long COVID/PASC (p=0.002).
Kruger 2022/South Africa	99 long COVID patients and 29 healthy controls. Median age of 51 [40–60] median age	Case control study	N/A	Constant fatigue: 74% Cognitive impairment ("brain fog" / forgetfulness / poor concentration): 71%; Dyspnoea 59% Arthralgia / myalgia: 49%; Sleep disturbance: 34% Depression / anxiety: 30% Heart rate dysfunction / palpitations: 30% Recurring chest pain: 29%; Anosmia (loss of smell) 25%; Dysgeusia: (loss of taste) 25%; Low oxygen levels 13%	Hypertension 24% Hyperlipidaemia 19% Type 2 diabetes mellitus 6%	N/A
Otmani et al., 2022/Marocco	118 healthcare workers who endured the Covid-19 infection and 118 matched controls. 71% were females. Average age-median (years) 29 (21–54)	case-control study	56/118 (47.4%)	At least one symptom 56(47.4%) Myalgia 13.3% Anxiety 21.7% Attention disorders, memory impairment "brain fog" 14.4% Sleep disorders 12% Palpitations 10.8% Arthralgia 9.6% Asthenia 25.3% Chest pain 8.4%	N/A	Pulmonary involvement in chest CT scan

				Anosmia/hyposmia 9.6%		
Zulu et al., 2022/Zambia	27 participants. Mean participant age was 32 years (range: 1-85 years). 17 (63.0%) were females	Prospective cohort study	27/182 (37%)	Cough 10 (37.0) Rhinorrhea 5 (18.5) Headache 7 (25.9) Chest pain 6 (22.2) Arthralgia 4 (14.8)	HIV 2(7.4%)	Those with five or more symptoms at onset had nearly (p=0.03) Participants with loss of appetite at symptoms onset (p=0.01).
Galal et al., 2021/Egypt	430 participants. They were 156 males and 274 females, their mean age was 37.4 ± 12.6 years, and the range was 12–74 years.	Cross-sectional study	268/430 (60%)	myalgia (60.0%), arthralgia (57.2%), restriction of daily activities (57.0%), and sleeping troubles (50.9%), followed by anorexia (42.6%), chest pain (32.6%), gastritis (32.3%), cough (29.3%), and dyspnea (29.1%).	Diabetes mellitus: 10.9% Hypertension: 15.10% Cardiac disease: 1.9% Chronic pulmonary disease: 5.3% Renal disease: 2.3% Psychiatric disease: 1.6%	Need of oxygen therapy (< 0.001) Hypertension (0.039) Any chronic illness (0.004)
Pretorius et al., 2022/ South Africa	845 participants The gender balance (70% female) and the most reported Long COVID/PASC symptoms. The majority (i.e., 76%) of the participants were between the ages of 31–40, 41–50, and 51– 60 years.	Retrospective cohort	N/A	Fatigue, brain fog, loss of concentration and forgetfulness, shortness of breath, as well as joint and muscle pains	Hypertension, high cholesterol levels (dyslipidaemia), cardiovascular disease and type 2 diabetes mellitus (T2DM)	Microclot and platelet pathologies were associated with Long COVID/PASC symptoms that persisted after the recovery from acute COVID-19.
Walker et al., 2022/South Africa	30 matched healthy subjects and 30 PASC subjects.	Case control study	N/A	N/A	N/A	Significant microclot load was observed in the PPP of participants with PASC
Turner et al., 2022/South Africa	25 Long COVID patients. 52 (±14) years. Females were predominant.	Case control study	N/A	N/A	Hypertension: 36% Hyperlipidaemia: 40% Type 2 Diabetes Mellitus: 12%	Presence of microclotting, together with relatively high levels of six inflammatory

	Cardiovascular	molecules known to
	disease: 8%	be key drivers of
	Thrombosis	endothelial and
	(previous blood	clotting pathology
	clots): 8%	
	Cancer: 12%	

# Supplementary material 1: Quality assessment of included studies

	Table 2. Quality as:	sessment of ir	ncluded studies.				
		Quality assessment criteria					
Author (year)	Study design	Selection	Comparability	Outcome/	Overall		
				exposure	quality		
Dryden et al., 2022	Prospective cohort study	****	**	**	8		
Mendelsohn et al.,	Retrospective cross-sectional	***	*	***	7		
2022	study						
Aly et al., 2021	Retrospective cross-sectional	**	*	**	5		
	study						
Crankson et al., 2022	Cross-Sectional Analysis	**	*	**	5		
Ogoina et al., 2021	Retrospective review	***	*	**	6		
Osikomaiya et al., 2021	Retrospective study design	**	*	**	5		
Pretorius et al., 2021	Case control study	**	*	**	5		
Kruger 2022	Case control study	***	*	***	7		
El Otmani et al., 2022	Case control study	***	**	*	6		
Zulu et al., 2022	Prospective cohort study	***	*	***	7		
Galal et al., 2021	Cross-sectional study	**	*	**	5		
Pretorius et al., 2022	Retrospective cohort	***	*	***	6		

Walker et al., 2022	Case control study	**	**	**	6
Turner et al., 2022	Case control study	**	*	***	6

Newcastle-Ottawa Scale was obtained to assess the selection, comparability and exposure of the case-control study, while the selection, comparability and outcome for the cohort study. -: no point; \*: one point; \*\*: two points; \*\*\*: three points; \*\*\*: four points.




Figure 1: Flow chart of studies reviewing long COVID in African populations




Figure 2: Forest plot of long COVID prevalence in African countries



Figure 1: Potential long COVID risk factors in Africa




Figure 3: Forest plot of predominant symptoms of long COVID in African populations